Type I interferon-delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+dendritic cells

被引：0
|
作者：
Kyoko, F. [1 ]
Nobuhiro, T. [2 ]
Tianyi, L. [3 ]
Satoru, S. [4 ]
Itaru, E. [2 ]
Tetsuya, N. [5 ]
Yasushi, U. [5 ]
机构：
[1] Natl Canc Ctr, Div Canc Immunotherapy, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[2] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa, Japan
[3] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[4] Kumamoto Univ, Fac Life Sci, Kumamoto, Japan
[5] Natl Canc Ctr, EPOC, Kashiwa, Chiba, Japan
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P1127
引用
收藏
页码：1797 / 1797
页数：1
相关论文
共 50 条
  • [1] Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells
    Tsuchiya, Nobuhiro
    Zhang, Rong
    Iwama, Tatsuaki
    Ueda, Norihiro
    Liu, Tianyi
    Tatsumi, Minako
    Sasaki, Yutaka
    Shimoda, Ranmaru
    Osako, Yuki
    Sawada, Yu
    Kubo, Yosuke
    Miyashita, Azusa
    Fukushima, Satoshi
    Cheng, Zhao
    Nakaki, Ryo
    Takubo, Keiyo
    Okada, Seiji
    Kaneko, Shin
    Ihn, Hironobu
    Kaisho, Tsuneyasu
    Nishimura, Yasuharu
    Senju, Satoru
    Endo, Itaru
    Nakatsura, Tetsuya
    Uemura, Yasushi
    CELL REPORTS, 2019, 29 (01): : 162 - +
  • [2] In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity
    Oba, Takaaki
    Ito, Kenichi
    CANCER SCIENCE, 2022, 113
  • [3] Therapeutically targeting type I interferon directly to XCR1+dendritic cells reveals the role of cDC1s in anti-drug antibodies
    Noe, Paul
    Wang, Joy H.
    Chung, Kyu
    Cheng, Zhiyong
    Field, Jessica J.
    Shen, Xiaomeng
    Cortesio, Christa L.
    Pastuskovas, Cinthia V.
    Phee, Hyewon
    Tarbell, Kristin V.
    Egen, Jackson G.
    Casbon, Amy-Jo
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity
    Liang, Yong
    Hannan, Raquibul
    Fu, Yang-Xin
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3818 - 3824
  • [5] In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
    Oba, Takaaki
    Makino, Kenichi
    Kajihara, Ryutaro
    Yokoi, Toshihiro
    Araki, Ryoko
    Abe, Masumi
    Minderman, Hans
    Chang, Alfred E.
    Odunsi, Kunle
    Ito, Fumito
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
  • [6] STING licensing of type I dendritic cells potentiates antitumor immunity
    Wang, Jian
    Li, Suxin
    Wang, Maggie
    Wang, Xu
    Chen, Shuqing
    Sun, Zhichen
    Ren, Xiubao
    Huang, Gang
    Sumer, Baran D.
    Yan, Nan
    Fu, Yang-Xin
    Gao, Jinming
    CANCER RESEARCH, 2024, 84 (07)
  • [7] STING licensing of type I dendritic cells potentiates antitumor immunity
    Wang, Jian
    Li, Suxin
    Wang, Maggie
    Wang, Xu
    Chen, Shuqing
    Sun, Zhichen
    Ren, Xiubao
    Huang, Gang
    Sumer, Baran D.
    Yan, Nan
    Fu, Yang-Xin
    Gao, Jinming
    SCIENCE IMMUNOLOGY, 2024, 9 (92)
  • [8] Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel, Jean-Charles
    Crozat, Karine
    Dalod, Marc
    Mattiuz, Raphael
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [9] The role of myeloid receptors on murine plasmacytoid dendritic cells in induction of type I interferon
    Seeds, Rosalind E.
    Mukhopadhyay, Subhankar
    Jones, Ian M.
    Gordon, Siamon
    Miller, Joanna L.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (07) : 794 - 801
  • [10] Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity
    Zeng, Y
    Feng, HP
    Graner, MW
    Katsanis, E
    BLOOD, 2003, 101 (11) : 4485 - 4491
12345